Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
Sept 22, 2021
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines. Samsung Biologics introduced its CDO process platform, S-Cellerate(TM), at BPI 2021 BPI 2021 took place both online and